Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Technically OTC devices

This article was originally published in The Tan Sheet

Executive Summary

Joint meeting of FDA's Ear, Nose & Throat and Dental Devices Panels will convene Oct. 6 to discuss data and labeling requirements for over-the-counter obstructive sleep apnea products and other issues related to OTC and prescription OSA device use. Separately, Philips Medical's HeartStart Home defibrillator is deemed safe enough to justify over-the-counter clearance by members of FDA's Circulatory System Devices Panel at a July 29 meeting. Concerns were raised, however, about use on patients with an implanted cardioverter defibrillator and pediatric use...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel